Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease
Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat i...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
AboutScience Srl
2014-01-01
|
| Series: | Drug Target Insights |
| Online Access: | https://doi.org/10.4137/DTI.S16524 |
| _version_ | 1819229224851996672 |
|---|---|
| author | Tetsu Akimoto Yoshiyuki Morishita Chiharu Ito Osamu Iimura Sadao Tsunematsu Yuko Watanabe Eiji Kusano Daisuke Nagata |
| author_facet | Tetsu Akimoto Yoshiyuki Morishita Chiharu Ito Osamu Iimura Sadao Tsunematsu Yuko Watanabe Eiji Kusano Daisuke Nagata |
| author_sort | Tetsu Akimoto |
| collection | DOAJ |
| description | Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time, that not only the serum levels of uric acid (UA) but also those of 8-hydroxydeoxyguanosine, an oxidative stress marker, were significantly reduced after six months of febuxostat treatment, with no adverse events. These results encouraged us to pursue further investigations regarding the clinical impact of lowering the serum UA levels with febuxostat in advanced CKD patients in terms of concomitantly reducing oxidative stress via the blockade of XO. More detailed studies with a larger number of subjects and assessments of the effects of multiple factors affecting hyperuricemia, such as age, sex, and dietary habits, would shed light on the therapeutic challenges of treating asymptomatic hyperuricemia in patients with various stages of CKD. |
| first_indexed | 2024-12-23T11:09:47Z |
| format | Article |
| id | doaj.art-e98289c4e2b0409ca6bfd8b391aff107 |
| institution | Directory Open Access Journal |
| issn | 1177-3928 |
| language | English |
| last_indexed | 2024-12-23T11:09:47Z |
| publishDate | 2014-01-01 |
| publisher | AboutScience Srl |
| record_format | Article |
| series | Drug Target Insights |
| spelling | doaj.art-e98289c4e2b0409ca6bfd8b391aff1072022-12-21T17:49:23ZengAboutScience SrlDrug Target Insights1177-39282014-01-01810.4137/DTI.S16524Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney DiseaseTetsu Akimoto0Yoshiyuki Morishita1Chiharu Ito2Osamu Iimura3Sadao Tsunematsu4Yuko Watanabe5Eiji Kusano6Daisuke Nagata7Green Town Clinic, Tochigi, Japan.Yuki Clinic, Ibaraki, Japan.Yuki Clinic, Ibaraki, Japan.Kumakura Clinic, Tochigi, Japan.Yuki Clinic, Ibaraki, Japan.Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.Division of Nephrology, Department of Internal Medicine, Jichi Medical University, Tochigi, Japan.Febuxostat is a nonpurine xanthine oxidase (XO) inhibitor, which recently received marketing approval. However, information regarding the experience with this agent among advanced chronic kidney disease (CKD) patients is limited. In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. We demonstrated, for the first time, that not only the serum levels of uric acid (UA) but also those of 8-hydroxydeoxyguanosine, an oxidative stress marker, were significantly reduced after six months of febuxostat treatment, with no adverse events. These results encouraged us to pursue further investigations regarding the clinical impact of lowering the serum UA levels with febuxostat in advanced CKD patients in terms of concomitantly reducing oxidative stress via the blockade of XO. More detailed studies with a larger number of subjects and assessments of the effects of multiple factors affecting hyperuricemia, such as age, sex, and dietary habits, would shed light on the therapeutic challenges of treating asymptomatic hyperuricemia in patients with various stages of CKD.https://doi.org/10.4137/DTI.S16524 |
| spellingShingle | Tetsu Akimoto Yoshiyuki Morishita Chiharu Ito Osamu Iimura Sadao Tsunematsu Yuko Watanabe Eiji Kusano Daisuke Nagata Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease Drug Target Insights |
| title | Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease |
| title_full | Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease |
| title_fullStr | Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease |
| title_full_unstemmed | Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease |
| title_short | Febuxostat for Hyperuricemia in Patients with Advanced Chronic Kidney Disease |
| title_sort | febuxostat for hyperuricemia in patients with advanced chronic kidney disease |
| url | https://doi.org/10.4137/DTI.S16524 |
| work_keys_str_mv | AT tetsuakimoto febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT yoshiyukimorishita febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT chiharuito febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT osamuiimura febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT sadaotsunematsu febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT yukowatanabe febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT eijikusano febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease AT daisukenagata febuxostatforhyperuricemiainpatientswithadvancedchronickidneydisease |